Pemvidutide

Pemvidutide is a peptide dual agonist that activates GLP-1 and glucagon receptors. The GLP-1 receptor agonism provides appetite suppression through central nervous system mechanisms (hypothalamic and brainstem satiety pathways), delays gastric emptying, and enhances glucose-dependent insulin secretion to counterbalance the hyperglycemic potential of glucagon. The glucagon receptor agonism drives increased hepatic fatty acid oxidation, reduced hepatic de novo lipogenesis, increased energy expenditure, and enhanced amino acid catabolism. The pronounced liver fat reduction seen in clinical trials reflects the direct hepatic effects of glucagon agonism on lipid metabolism. The relative potency ratio between GLP-1 and glucagon receptor activity is designed to optimize weight loss and hepatic benefit while maintaining glycemic neutrality or improvement.

Phase 2 data in adults with overweight/obesity demonstrated approximately 15.6% total body weight loss at 48 weeks with the 2.4 mg weekly dose. Phase 2a data in patients with MAFLD showed hepatic fat fraction reductions exceeding 70% from baseline, with normalization of ALT in the majority of patients. These liver-specific results are notable and position pemvidutide as a potential treatment for MAFLD and MASH. The compound has advanced to later-stage development, though full Phase 2 peer-reviewed publications are still emerging. Limitations include limited sample sizes, absence of liver biopsy endpoints (imaging-based liver fat assessment was used), and the early stage of clinical development.

Pemvidutide is in clinical development under Altimmune, Inc. It has not received FDA or EMA approval. The development program is focused on obesity and MAFLD/MASH. The compound is not available outside of clinical trials. Altimmune has reported data at major medical conferences but peer-reviewed full publications are still forthcoming for some datasets.

Monitor hepatic function tests (ALT, AST, GGT) and liver fat content if imaging is available. Track body weight, HbA1c, fasting glucose, and lipid panel (including LDL cholesterol). Assess GI tolerability during dose titration. Heart rate and blood pressure monitoring is appropriate. Given the early development stage, clinicians should remain alert for unexpected safety signals.

These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.

Investigational product. Not commercially available. Stability and handling parameters are governed by clinical trial protocols and are not publicly disclosed.

1. 1

   RCT

   Pemvidutide (ALT-801) Phase 2 Trial for Obesity: 48-Week Results

   Altimmune Inc. (2024). EASL Congress / Altimmune Press Release

   Key findings: Phase 2 trial in adults with overweight/obesity. Pemvidutide 2.4 mg weekly achieved approximately 15.6% total body weight loss at 48 weeks. Notable reductions in liver fat content (up to 78% reduction) and ALT normalization in the majority of patients.

   Limitations: Phase 2 data. Limited sample size. Full peer-reviewed publication pending.

2. 2

   RCT

   Pemvidutide Phase 2a Trial in MAFLD

   Tillman EJ, Rolph T, et al. (2023). Obesity

   Key findings: Phase 2a data showing significant liver fat reduction in patients with MAFLD. Mean hepatic fat fraction decreased by over 70% from baseline. Improvements in hepatic and metabolic biomarkers.

   Limitations: Small sample size. Phase 2a. Open-label component.